These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23836634)

  • 21. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Oncolytic parvoviruses. A new approaches for cancer therapy].
    Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
    Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
    Goetz C; Gromeier M
    Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
    Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
    Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral vectors: promising new therapeutics in the battle against glioblastoma.
    Salehi A; Chen CC; Carter BS
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):489-91. PubMed ID: 23121267
    [No Abstract]   [Full Text] [Related]  

  • 26. The Oncolytic Virus G47Δ Shows Efficacy and Safety in Glioblastoma.
    Cancer Discov; 2022 Oct; 12(10):OF4. PubMed ID: 35929750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D; Martuza RL; Rabkin SD
    Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic adenoviral therapy for glioblastoma multiforme.
    Sonabend AM; Ulasov IV; Han Y; Lesniak MS
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Poliovirus for Cancer Immunotherapy.
    Gromeier M; Nair SK
    Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for glioblastoma: going viral.
    Iorgulescu JB; Reardon DA; Chiocca EA; Wu CJ
    Nat Med; 2018 Aug; 24(8):1094-1096. PubMed ID: 30082860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
    Alvarez-Breckenridge CA; Yu J; Price R; Wojton J; Pradarelli J; Mao H; Wei M; Wang Y; He S; Hardcastle J; Fernandez SA; Kaur B; Lawler SE; Vivier E; Mandelboim O; Moretta A; Caligiuri MA; Chiocca EA
    Nat Med; 2012 Dec; 18(12):1827-34. PubMed ID: 23178246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.
    Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M
    Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889
    [No Abstract]   [Full Text] [Related]  

  • 35. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for thoracic oncology gone viral.
    Patel MR
    Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.
    Kroeger KM; Muhammad AK; Baker GJ; Assi H; Wibowo MK; Xiong W; Yagiz K; Candolfi M; Lowenstein PR; Castro MG
    Discov Med; 2010 Oct; 10(53):293-304. PubMed ID: 21034670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
    Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
    Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.